Richmond News Now

Tuberculosis Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

 Breaking News
  • No posts were found

Tuberculosis Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

March 13
20:10 2023
Tuberculosis Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

DelveInsight’s, “Tuberculosis Pipeline Insight 2023,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in the Tuberculosis pipeline landscape. It covers the Tuberculosis pipeline drug profiles, including Tuberculosis clinical trials and nonclinical stage products. It also covers the Tuberculosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Tuberculosis Emerging drugs, the Tuberculosis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Tuberculosis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Tuberculosis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Tuberculosis clinical trials studies, Tuberculosis NDA approvals (if any), and product development activities comprising the technology, Tuberculosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Tuberculosis Pipeline Report

 

  • DelveInsight’s Tuberculosis Pipeline analysis depicts a robust space with 35+ active players working to develop 35+ pipeline therapies for Tuberculosis treatment.

 

  • The leading Tuberculosis companies include Serum Institute of India Pvt. Ltd., AnHui Longcom Biologic Pharmacy, Biofabri, S.L, Immunitor LLC, Shanghai Jiatan Pharmatech, GlaxoSmithKline, Archivel Farma S.L., LegoChem Biosciences, Quratis Inc, Qurient Co., Sequella, Inc., Vaxil Biotherapeutics, Tianjin CanSino Biotechnology, Global Alliance for TB Drug Development, BioNtech, TaBriX, Moderna, GC Biopharma, AJ Vaccines, Vaxxit Srl, Vaxil Bio Therapeutics, Vaxine Pty Ltd,  TVAX Biomedical, Theravectys SA, Tydockpharma, PDS Biotechnology, PAI lifesciences, EpiVax, Inc., GlobeImmune Inc., Zymergen, Jiangsu Recbio Technology, and others.

 

  • Promising Tuberculosis pipeline therapies include VPM1002, MTBVAC, ESAT-CFP10, V7, WX-081, GSK 692342, GSK3036656, RUTI, LCB01-0371, ID 93, AERAS-404, Telacebec, Sutezolid, OPC-167832, Tuberculosis Vaccine, TBA 7371, TBAJ-876, SPR720, BNT164, GSK2556286, GC3107A, MTbuVax, PDS0201, GI19000, REC 607, and others.

 

  • The Tuberculosis companies and academics are working to assess challenges and seek opportunities that could influence Tuberculosis R&D. The Tuberculosis pipeline therapies under development are focused on novel approaches to treat/improve Tuberculosis. 

 

Request a sample and discover the recent breakthroughs happening in the Tuberculosis Pipeline landscape @ Tuberculosis Pipeline Outlook Report

 

Tuberculosis Overview

Tuberculosis (TB) is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain. Not everyone infected with TB bacteria becomes sick. As a result, two TB-related conditions exist: latent TB infection (LTBI) and TB disease.

 

Recent Developmental Activities in the Tuberculosis Treatment Landscape

 

  • In January 2022, GlaxoSmithKline’s GSK-3036656 saw its Phase Transition Success Rate (PTSR) climb seven points to 55% after its Phase II pulmonary tuberculosis trial was completed.

 

  • In March 2022, Bharat Biotech announced a partnership with Biofabri, a Spanish biopharmaceutical company, to develop, manufacture and market a new tuberculosis vaccine ‘MTBVAC’. The partnership guarantee the supply of TB vaccines in more than 70 countries, especially in Southeast Asia and sub-Saharan Africa.

 

  • In April 2022, Moderna and the nonprofit scientific research organization IAVI entered into a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats, including HIV/AIDS, tuberculosis (TB), and antimicrobial-resistant enteric infections, and COVID-19.

 

  • TaBriX and The University of Manchester are working in collaboration with TB Alliance to assess how effective TB drug candidates are alone and in combination with the current standard of care. TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs to fight difficult-to-treat infections.

 

  • Zymergen has demonstrated early results from its infectious disease program, supported by a grant from the Bill & Melinda Gates Foundation, which discovered hundreds of potential novel hits against malaria, tuberculosis, and COVID-19 targets.

 

For further information, refer to the detailed Tuberculosis Drugs Launch, Tuberculosis Developmental Activities, and Tuberculosis News, click here for Tuberculosis Ongoing Clinical Trial Analysis

 

Tuberculosis Emerging Drugs Profile

 

  • Telacebec (Q203): Qurient Co

Telacebec (Q203) is one of the first candidates getting close to forming new universal regimen. Telacebec (Q203) is an orally active small molecule drug candidate that blocks Mycobacterium tuberculosis growth by inhibiting cytochrome bc1 complex, leading to the depletion of adenosine triphosphate (ATP) synthesis of M. tuberculosis. Telacebec (Q203) shows good synergy with bedaquiline in murine chronic infection model, indicating promising potential for new drug regimen. The drug is currently in phase 2 stage of development.

 

  • VPM1002: Serum Institute of India

VPM1002 facilitates mycobacterial antigens being released into the cytosol while also triggering autophagy, inflammasome activation, and apoptosis, because of antigens and bacterial DNA being released into the cytosol of the host cell due to Listeriolysin O expression in this vaccine. Mycobacterial antigen accessing the cytosol also improves antigen presentation. The ability for mycobacterial antigens to reach the cytosol is due to this vaccine being engineered to secrete Hly which perforates phagosomal membranes. Currently, it is in phase III stage of development for the treatment of Tuberculosis.

 

Tuberculosis Pipeline Therapeutics Assessment

There are approx. 35+ key companies which are developing the therapies for Tuberculosis. The companies which have their Tuberculosis drug candidates in the mid to advanced stage, i.e. Phase III include, Qurient Co

 

Find out more about the Tuberculosis Pipeline Segmentation, Therapeutics Assessment, and Tuberculosis Emerging Drugs @ Tuberculosis Treatment Landscape

 

Scope of the Tuberculosis Pipeline Report

 

  • Coverage- Global

 

  • Tuberculosis Companies- Serum Institute of India Pvt. Ltd., AnHui Longcom Biologic Pharmacy, Biofabri, S.L, Immunitor LLC, Shanghai Jiatan Pharmatech, GlaxoSmithKline, Archivel Farma S.L., LegoChem Biosciences, Quratis Inc, Qurient Co., Sequella, Inc., Vaxil Biotherapeutics, Tianjin CanSino Biotechnology, Global Alliance for TB Drug Development, BioNtech, TaBriX, Moderna, GC Biopharma, AJ Vaccines, Vaxxit Srl, Vaxil Bio Therapeutics, Vaxine Pty Ltd,  TVAX Biomedical, Theravectys SA, Tydockpharma, PDS Biotechnology, PAI lifesciences, EpiVax, Inc., GlobeImmune Inc., Zymergen, Jiangsu Recbio Technology, and others.

 

  • Tuberculosis Pipeline Therapies- VPM1002, MTBVAC, ESAT-CFP10, V7, WX-081, GSK 692342, GSK3036656, RUTI, LCB01-0371, ID 93, AERAS-404, Telacebec, Sutezolid, OPC-167832, Tuberculosis Vaccine, TBA 7371, TBAJ-876, SPR720, BNT164, GSK2556286, GC3107A, MTbuVax, PDS0201, GI19000, REC 607, and others

 

  • Tuberculosis Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Tuberculosis Pipeline Companies and Therapies, click here @ Tuberculosis Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Tuberculosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Telacebec (Q203): Qurient Co
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II) 
  10. WX-081: Shanghai Jiatan Pharmatech
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I/II)
  13. OPC-167832: Otsuka Pharmaceutical
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Tuberculosis Key Companies
  17. Tuberculosis Key Products
  18. Tuberculosis- Unmet Needs
  19. Tuberculosis- Market Drivers and Barriers
  20. Tuberculosis- Future Perspectives and Conclusion
  21. Tuberculosis Analyst Views
  22. Tuberculosis Key Companies
  23. Appendix

  

Got Queries? Find out the related information on Tuberculosis Mergers and acquisitions, Tuberculosis Licensing Activities @ Tuberculosis Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories